Do Allergic Comorbidities Alter the Efficacy and Safety of Abrocitinib or Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis?

Abstract Introduction Allergic comorbidities are common in patients with atopic dermatitis (AD). Individual trials with abrocitinib or dupilumab demonstrated efficacy and safety in patients with moderate-to-severe AD and allergic comorbidities. This post hoc analysis of the phase 3 JADE COMPARE and...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Eric L. Simpson, Jonathan I. Silverberg, Bob Geng, José-Manuel Carrascosa, Thomas Bieber, Patrick M. Brunner, Delphine Staumont-Sallé, Chao Ji, Pinaki Biswas, Claire Feeney, Irene Hernández-Martín, Francisco José Rebollo Laserna, Herwig Koppensteiner
Format: Artigo
Jezik:Inglês
Izdano: Adis, Springer Healthcare 2025-09-01
Serija:Dermatology and Therapy
Teme:
Abrocitinib
Allergic rhinitis
Asthma
Comorbidity
Dupilumab
Food allergy
Online pristup:https://doi.org/10.1007/s13555-025-01516-w
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items